Algernon Pharmaceuticals Begins Screening Patients for Phase 2 Chronic Cough and IPF Study
Algernon Pharmaceuticals begins screening patients for Phase 2 chronic cough and IPF study
Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has begun screening patients in Australia for a Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study with their repurposed drug Ifenprodil.
Moreau shared details about that study and he also takes a broader look at the drug Ifenprodil and the number of studies the company is undertaking to see it’s effectiveness in treating respiratory conditions.
